SUTRO BIOPHARMA, INC. (STRO) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $17.00K; Additional Paid in Capital, Common StockUSD $951.70M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-58.00K; Retained Earnings (Accumulated Deficit)USD $-1.05B.
- 2026-03-31: Common Stock, Value, IssuedUSD $17.00K; Additional Paid in Capital, Common StockUSD $949.64M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-101.00K; Retained Earnings (Accumulated Deficit)USD $-1.02B.
- 2025-12-31: Common Stock, Value, IssuedUSD $9.00K; Additional Paid in Capital, Common StockUSD $845.48M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $19.00K; Retained Earnings (Accumulated Deficit)USD $-977.96M.
- 2025-09-30: Common Stock, Value, IssuedUSD $85.00K; Additional Paid in Capital, Common StockUSD $843.81M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $33.00K; Retained Earnings (Accumulated Deficit)USD $-931.19M.
SUTRO BIOPHARMA, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $17.00K | $951.70M | $-58.00K | $-1.05B | $-103.32M | 3 month · $2.01M | (m) |
| 2026-03-31 | $17.00K | $949.64M | $-101.00K | $-1.02B | $-66.89M | 3 month · $1.56M | (m) |
| 2025-12-31 | $9.00K | $845.48M | $19.00K | $-977.96M | $-132.45M | 12 month · $14.01M | (m) |
| 2025-09-30 | $85.00K | $843.81M | $33.00K | $-931.19M | $-87.27M | 3 month · $1.55M | (m) |
| 2025-06-30 | $85.00K | $842.15M | $-13.00K | $-874.34M | $-32.11M | 3 month · $5.26M | (m) |
| 2025-03-31 | $84.00K | $836.95M | $-9.00K | $-862.84M | $-25.81M | 3 month · $5.54M | (m) |
| 2024-12-31 | $8.00K | $831.42M | $39.00K | $-786.87M | $44.60M | 12 month · $24.69M | (m) |
| 2024-09-30 | $82.00K | $825.46M | $106.00K | $-714.43M | $111.22M | 3 month · $6.54M | (m) |
| 2024-06-30 | $82.00K | $817.90M | $-163.00K | $-665.64M | $152.18M | 3 month · $6.16M | (m) |
| 2024-03-31 | $62.00K | $715.70M | $-113.00K | $-617.62M | $98.02M | 3 month · $6.07M | (m) |
| 2023-12-31 | $61.00K | $708.98M | $21.00K | $-559.41M | $149.65M | 12 month · $24.91M | (m) |
| 2023-09-30 | $61.00K | $702.75M | $7.00K | $-590.47M | $112.43M | 3 month · $6.00M | (m) |
| 2023-06-30 | $60.00K | $695.83M | $16.00K | $-541.19M | $154.72M | 3 month · $6.66M | (m) |
| 2023-03-31 | $60.00K | $688.12M | $-107.00K | $-502.67M | $185.41M | 3 month · $6.02M | (m) |
| 2022-12-31 | $58.00K | $670.22M | $-618.00K | $-452.62M | $217.05M | 12 month · $26.30M | (m) |
| 2022-09-30 | $55.00K | $649.03M | $-1.34M | $-418.02M | $229.73M | 3 month · $6.78M | (m) |
| 2022-06-30 | $49.00K | $608.90M | $-1.36M | $-398.53M | $209.06M | 3 month · $6.70M | (m) |
| 2022-03-31 | $47.00K | $594.00M | $-1.15M | $-372.52M | $220.37M | 3 month · $6.97M | (m) |
| 2021-12-31 | $46.00K | $586.24M | $-314.00K | $-333.41M | $252.56M | 12 month · $23.24M | (m) |
| 2021-09-30 | $46.00K | $578.85M | $-30.00K | $-295.29M | $283.58M | 3 month · $6.50M | (m) |
| 2021-06-30 | $46.00K | $571.88M | $-45.00K | $-264.38M | $307.50M | 3 month · $5.91M | (m) |
| 2021-03-31 | $46.00K | $565.52M | (m) | $-258.23M | $307.34M | 3 month · $3.95M | (m) |
| 2020-12-31 | $46.00K | $559.75M | $129.00K | $-227.87M | $332.05M | 12 month · $11.92M | (m) |
| 2020-09-30 | $38.00K | $412.17M | $237.00K | $-168.33M | $244.12M | 3 month · $3.11M | (m) |
| 2020-06-30 | $36.00K | $391.79M | $398.00K | $-185.47M | $206.76M | 3 month · $3.01M | (m) |
| 2020-03-31 | $23.00K | $297.37M | $28.00K | $-215.34M | $82.08M | 3 month · $2.71M | (m) |
| 2019-12-31 | $23.00K | $293.35M | $165.00K | $-195.75M | $97.79M | 12 month · $10.31M | (m) |
| 2019-09-30 | $23.00K | $290.62M | $223.00K | $-180.96M | $109.91M | 3 month · $2.88M | (m) |
| 2019-06-30 | $23.00K | $287.36M | $213.00K | $-168.04M | $119.56M | 3 month · $2.46M | (m) |
| 2019-03-31 | $23.00K | $284.89M | $56.00K | $-154.25M | $130.72M | 3 month · $2.29M | (m) |
| 2018-12-31 | $23.00K | $281.89M | $-47.00K | $-150.33M | $131.54M | 12 month · $2.87M | 12 month · $734.00K |
| 2018-09-30 | (m) | $7.43M | $-27.00K | $-148.84M | $-141.43M | 3 month · $321.00K | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | $-132.02M | 3 month · $232.00K | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | $-120.75M | 3 month · $249.00K | (m) |
| 2017-12-31 | (m) | $6.22M | (m) | $-115.01M | $-109.00M | 12 month · $1.39M | (m) |
| 2016-12-31 | (m) | (m) | (m) | (m) | $-90.90M | 12 month · $968.00K | (m) |
| 2015-12-31 | (m) | (m) | (m) | (m) | $-93.90M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |